Peak6 LLC Buys Shares of 31,884 Enovis Co. (NYSE:ENOV)

PEAK6 LLC purchased a new stake in Enovis Co. (NYSE:ENOV - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 31,884 shares of the company's stock, valued at approximately $1,399,000. PEAK6 LLC owned approximately 0.06% of Enovis at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Gamco Investors INC. ET AL raised its stake in Enovis by 10.1% during the 4th quarter. Gamco Investors INC. ET AL now owns 8,828 shares of the company's stock worth $387,000 after acquiring an additional 809 shares in the last quarter. Keeley Teton Advisors LLC lifted its holdings in shares of Enovis by 89.2% in the 4th quarter. Keeley Teton Advisors LLC now owns 11,930 shares of the company's stock valued at $523,000 after purchasing an additional 5,624 shares during the last quarter. Mariner LLC grew its stake in Enovis by 16.8% during the 4th quarter. Mariner LLC now owns 7,925 shares of the company's stock worth $348,000 after buying an additional 1,142 shares during the last quarter. Sterling Capital Management LLC increased its position in Enovis by 56.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock worth $143,000 after buying an additional 1,173 shares during the period. Finally, Kennedy Capital Management LLC boosted its holdings in shares of Enovis by 5.8% in the fourth quarter. Kennedy Capital Management LLC now owns 158,557 shares of the company's stock valued at $6,957,000 after acquiring an additional 8,743 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Performance

Shares of NYSE:ENOV traded down $0.15 during midday trading on Friday, hitting $34.97. The stock had a trading volume of 261,469 shares, compared to its average volume of 746,116. Enovis Co. has a 1 year low of $29.32 and a 1 year high of $56.43. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The stock has a 50 day moving average price of $36.70 and a two-hundred day moving average price of $41.98. The company has a market capitalization of $2.00 billion, a PE ratio of -15.95 and a beta of 1.86.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. As a group, equities analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a "buy" rating and set a $64.00 price objective on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.